Observational studyPloS one2019

Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.

Yusuke Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.